CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have received a consensus rating of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.77.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th.

Institutional Trading of CytomX Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Congress Park Capital LLC raised its holdings in CytomX Therapeutics by 393.3% in the 2nd quarter. Congress Park Capital LLC now owns 1,153,220 shares of the biotechnology company’s stock valued at $1,407,000 after buying an additional 919,420 shares during the period. Assenagon Asset Management S.A. increased its position in shares of CytomX Therapeutics by 206.0% during the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock valued at $1,511,000 after acquiring an additional 833,825 shares during the last quarter. Sei Investments Co. purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at approximately $467,000. Candriam S.C.A. acquired a new position in shares of CytomX Therapeutics in the 2nd quarter worth approximately $256,000. Finally, Virtu Financial LLC purchased a new position in shares of CytomX Therapeutics during the 3rd quarter worth approximately $104,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Trading Up 3.9 %

NASDAQ:CTMX opened at $1.06 on Monday. The stock has a 50 day moving average of $1.06 and a two-hundred day moving average of $1.27. CytomX Therapeutics has a 12 month low of $0.83 and a 12 month high of $5.85. The firm has a market cap of $82.96 million, a P/E ratio of 6.24 and a beta of 1.06.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.23. The firm had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the previous year, the business earned $0.04 earnings per share. On average, research analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.